Biocon and Mylan’s Ogivri (trastuzumab, biosimilar) Receives Health Canada’s Approval for HER2-Positive Breast and Gastric Cancers

Biocon and Mylan’s Ogivri (trastuzumab, biosimilar) Receives Health Canada’s Approval for HER2-Positive Breast and Gastric Cancers

Shots:

  • The approval is based on study assessing Ogivri vs Herceptin (trastuzumab) in patients evaluating its safety, efficacy, PK and immunogenicity
  • The study resulted with no clinical difference in safety, efficacy and potency between Ogivri and Herceptin
  • Ogivri (trastuzumab, biosimilar) is a mAb, currently approved in 65 countries including the US. Ogivri is one of the six biosimilar and second approved product co-developed by Biocon and Mylan . In Q2’19 Mylan plans to launch Ogivri in Canada

Click here to read full press release/ article | Ref: Biocon | Image:Pittsburgh Post-Gazette